In Phase A, individuals will get different doses and schedules of oral ABBV-744 tablet to establish Harmless dosing regimen. Added contributors might be enrolled on the identified monotherapy dosign regimen. In Segment B, members will acquire oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Segment C, participants https://travisqeqbn.nizarblog.com/32082140/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml